Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)
Sponsors
NewAmsterdam Pharma B.V.
Conditions
Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)Atherosclerotic Cardiovascular Disease
Phase 3
A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants with Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT trial)
RecruitingCTIS2023-508475-36-00
Start: 2024-10-29Target: 250Updated: 2025-10-30
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS trial)
Not yet recruitingCTIS2025-521936-12-00
Target: 118Updated: 2026-04-01